Obesity News

Adults with diabetes who used a GLP-1 receptor agonist and underwent surgery requiring general anesthesia had similar odds for postsurgical complications as those receiving other oral diabetes medications, according to study data.

Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial.

WASHINGTON — Parental obesity was associated with a nearly threefold increased risk for metabolic dysfunction-associated steatotic liver disease among offspring in early adulthood, according to data presented at Digestive Disease Week.

WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.

The disease of obesity often brings cardiometabolic consequences, including hypertension, which remains the most potent and predictive risk factor for cardiovascular disease.

Today, we are closer than ever to achieving the weight loss seen with bariatric surgery, and we are starting to see emerging evidence of cardiovascular risk reduction, type 2 diabetes remission, improvement in heart failure with preserved ejection fraction (HFpEF) and more. This “new” class of medications has been around for more than 18 years. We know the safety profiles; they are manageable.

Last month, the Obesity Medicine Association held its annual conference, where clinicians across the country came together to discuss the latest developments in obesity care.

Individuals prescribed the antidiabetes treatment metformin less likely developed a myeloproliferative neoplasm —potentially also reducing a person’s chances for developing certain cancers — according to data published in Blood Advances.

In patients with type 2 diabetes who underwent ablation for atrial fibrillation, those taking a GLP-1 receptor agonist had lower risk for AF recurrence, mortality and other outcomes, researchers reported at Heart Rhythm 2024.